chemieunternehmen.com

Evotec AG and Conba Pharmaceutical Co., Ltd. announced today the grant of a development and marketing license on EVT 401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease and endometriosis in China. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-grants-exclusive-rights-on-evt-401-in-china-to-conba-pharmaceutical-5053

Evotec AG today announced that it has extended and expanded its medicinal chemistry collaboration with Active Biotech AB, to further advance an existing programme, which has entered the lead optimisation phase. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-active-biotech-extend-and-expand-medicinal-chemistry-collaboration-5051

Evotec AG today announced the publication of its second edition of DDup, which focuses on neurodegeneration diseases, major disorders with inadequate standards of care.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-2—neurodegenerative-diseases-5048

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2011. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-fy-2011-significant-growth-and-focused-investments-drive-profitability-and-innovation-5047

Evotec AG and IR Pharma today announced that they have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ir-pharma-establish-drug-discovery-alliance-in-the-field-of-respiratory-5043

Evotec AG today announced the completion of the squeeze-out process to acquire all of the remaining shares of DeveloGen AG from its minority shareholders. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/squeeze-out-process-for-develogen-completed-5041

Evotec AG today announced a second strategic alliance with Harvard University, this time including Brigham and Women’s Hospital aimed at discovering and developing new biomarkers and treatments in the field of kidney disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-harvard-university-expand-strategic-alliance-into-kidney-disease-5039

Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 2.5 million to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-4th-milestone-payment-in-2011-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-5037

Evotec AG today reported financial results and corporate updates for the first nine months of 2011. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/nine-months-results-upside-materialising-5034